Verrica Pharmaceuticals Inc.
VRCA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $36,266 | $331,907 | $93,949 | $247,727 |
| - Cash | $46,329 | $69,547 | $34,273 | $15,752 |
| + Debt | $45,939 | $45,510 | $1,526 | $43,409 |
| Enterprise Value | $35,876 | $307,870 | $61,202 | $275,384 |
| Revenue | $7,566 | $5,124 | $9,032 | $12,000 |
| % Growth | 47.7% | -43.3% | -24.7% | – |
| Gross Profit | $4,826 | $4,378 | $8,307 | $11,528 |
| % Margin | 63.8% | 85.4% | 92% | 96.1% |
| EBITDA | -$65,898 | -$62,197 | -$21,597 | -$30,313 |
| % Margin | -871% | -1,213.8% | -239.1% | -252.6% |
| Net Income | -$76,579 | -$66,995 | -$24,487 | -$35,080 |
| % Margin | -1,012.1% | -1,307.5% | -271.1% | -292.3% |
| EPS Diluted | -14.78 | -14.78 | -7.17 | -12.97 |
| % Growth | 0% | -106.1% | 44.7% | – |
| Operating Cash Flow | -$60,927 | -$38,577 | -$18,650 | -$27,582 |
| Capital Expenditures | -$27 | -$362 | -$302 | -$883 |
| Free Cash Flow | -$60,954 | -$38,939 | -$18,952 | -$28,465 |